Unlocking the Potential of Digital Biomarkers to Overcome Biological Variability of Mood & Behaviour & Drive More Reliable Patient Selection

Time: 11:00 am
day: Track 2 AM Day 1


  • Emphasizing the clinical value of objective and continuous measurements with wearable sensors
  • Challenges and pitfalls in developing minimal burden portable biomarker assessment tools
  • Selecting the right digital measures to identify and enrich patient population and generate Phase 1 through Phase 3 data
  • Capturing trait and/or state digital markers: the value of longitudinal assessments from Phase 1 to Phase 3 in drug development